全文获取类型
收费全文 | 372篇 |
免费 | 18篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 5篇 |
妇产科学 | 7篇 |
基础医学 | 15篇 |
临床医学 | 28篇 |
内科学 | 123篇 |
皮肤病学 | 1篇 |
神经病学 | 1篇 |
特种医学 | 6篇 |
外科学 | 6篇 |
综合类 | 109篇 |
预防医学 | 22篇 |
眼科学 | 7篇 |
药学 | 36篇 |
1篇 | |
中国医学 | 25篇 |
肿瘤学 | 2篇 |
出版年
2024年 | 5篇 |
2023年 | 14篇 |
2022年 | 10篇 |
2021年 | 13篇 |
2020年 | 10篇 |
2019年 | 21篇 |
2018年 | 3篇 |
2017年 | 5篇 |
2016年 | 7篇 |
2015年 | 4篇 |
2014年 | 18篇 |
2013年 | 18篇 |
2012年 | 19篇 |
2011年 | 20篇 |
2010年 | 13篇 |
2009年 | 16篇 |
2008年 | 25篇 |
2007年 | 17篇 |
2006年 | 10篇 |
2005年 | 8篇 |
2004年 | 16篇 |
2003年 | 17篇 |
2002年 | 19篇 |
2001年 | 18篇 |
2000年 | 16篇 |
1999年 | 10篇 |
1998年 | 7篇 |
1997年 | 6篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 3篇 |
排序方式: 共有394条查询结果,搜索用时 15 毫秒
41.
目的 比较门冬胰岛素(IAsp)和可溶性人胰岛素(HI)分别联合中性鱼精蛋白胰岛素(NPH)在糖尿病治疗中的有效性和安全性.方法 220例来自全国5家医院的1型(T1DM)或2型糖尿病(T2DM)患者按1:1的比例随机分为两组,分别接受IAsp或HI联合NPH治疗.以空腹血糖(FPG)、餐后2 h血糖(2h PPG)、糖化血红蛋白(HbA1c)及低血糖事件作为评价指标.结果 IAsp/NPH组[(14.6±5.3)mmol/L比(8.4±4.1)nunol/L]较HI/NPH组治疗后2 h PPG改善更为显著[(14.9±3.9)mmol/L比(10.6±3.5)mmoL/L,P<0.05],且达标率分别为50.0%、25.5%(P<0.01).治疗后IAsp/NPH组[(9.3±1.4)%比(7.7±1.3)%]和HI/NPH组[(9.2±1.2)%比(7.7±1.2)%]HbA1c明显下降,但两组比较差异无统计学意义(P=0.437).达标率分别为24.5%和14.5%(P<0.05).在Imp/NPH组未见严重低血糖事件和其他不良事件,且夜间低血糖发生率更低(IAsp/NPH:3%,HI/NPH:4%).IAap/NPH组与HI/NPH组患者胰岛素日均剂量分别是0.60/0.23 IU/kg和0.65/0.24 IU/kg.结论 IAsp联合NPH能更好地控制餐后血糖,提高患者血糖达标率且不增加夜间低血糖和不良事件的风险. 相似文献
42.
43.
格列美脲治疗2型糖尿病安全性和有效性的多中心临床研究 总被引:11,自引:0,他引:11
目的 评价格列美脲对单纯饮食或用二甲双胍和/或阿卡波糖治疗控制不满意的2型糖尿病治疗的安全性、耐受性和有效性。方法 用多中心、开放性、非对照性临床研究,入选患者给予格列美脲1~4 mg,每日早餐前顿服,疗程16周。试验前后测定血糖、糖化血红蛋白、血脂和肝肾功能。结果129例患者人选,122例患者完成试验,格列美脲治疗16周空腹和餐后2h血糖平均分别下降1.3和1.8 mmol·L~(-1),糖化血红蛋白平均下降1.8%。治疗后空腹血浆胰岛素水平无变化,HOMA胰岛素抵抗指数明显下降,患者体重指数平均增加0.3 kg·m~(-2)。与格列美脲治疗有关的主要不良事件为低血糖反应和消化道症状,16例次与药物有关的低血糖反应均为轻度,进食后可自行缓解。对血脂和血压无不良影响。结论 格列美脲可以进一步降低单纯饮食控制或应用二甲双胍和/或阿卡波糖治疗的2型糖尿病患者的空腹和餐后2h时血糖以及糖化血红蛋白,且不增加空腹胰岛素水平,副作用小,耐受性好,使用较安全。 相似文献
44.
目的探讨血管细胞黏附分子(vascular cell adhesion molecule-1,VCAM-1)及胰高血糖素样肽-1(glucagon like peptide-1,GLP-1)水平与妊娠期糖尿病孕妇不良妊娠结局的相关性。方法选择2016年1月至2019年1月在邢台市第三医院诊治的妊娠期糖尿病患者140例为观察组,同期产检正常孕妇140例为对照组。两组在入组后第2 d清晨空腹采集肘部静脉血,比较两组VCAM-1、GLP-1水平、妊娠结局及其相关性。结果观察组血清VCAM-1水平显著高于对照组,GLP-1水平显著低于对照组,差异有统计学意义(P<0.05);观察组的巨大儿、新生儿低血糖、剖宫产率显著高于对照组(P<0.05);对观察组进行多因素Logistic回归分析显示,VCAM-1水平升高(OR=3.106,P=0.017,95%CI:2.542-4.549),GLP-1水平降低(OR=2.674,P=0.024,95%CI:1.159-3.631)是不良母婴结局的危险因素。结论妊娠期糖尿病患者中血清VCAM-1、GLP-1水平发生较大变化,是不良妊娠结局的危险因素,在临床上可加强妊娠期糖尿病相关指标的监测,制定合理的治疗措施干预妊娠的结局。 相似文献
45.
不同糖耐量人群胰岛素抵抗和胰岛β细胞功能减退的差异 总被引:1,自引:0,他引:1
目的探讨不同糖耐量人群胰岛素抵抗(IR)和胰岛B细胞功能状态。方法分析5523例患者行OGTT和胰岛素释放试验的结果,根据WHO标准将研究对象分为糖代谢正常(NGT)组、单纯空腹血糖升高(IFG)组、单纯糖耐量减低(IGT)组、空腹血糖升高合并糖耐量受损(IFG+IGT)组和2型糖尿病(T2DM)组。结果(1)HOMA-IR:IFG、IGT、IFG+IGT和T2DM组比NGT组分别增加41%、19%、47%和69%(P〈0.01)。(2)校正IR影响后,IFG、IGT、IFG+IGT和T2DM组比NGT组HOMA-β分别下降54%、19%、55%和68%,△I30/△G30分别下降47%、40%、63%和82%(P〈0.001);IFG、IFG+IGT和T2DM组AUCI比NGT组分别下降27%、26%和30%(P〈0.01)。结论(1)从IGT、IFG、IFG+IGT到T2DM发展过程中IR程度逐渐加重,胰岛β细胞早时相分泌和基础分泌功能逐渐衰竭,晚时相分泌代偿能力功能减弱,总体分泌功能逐渐减退。(2)从NGT、IGT、IFG、IFG+IGT到T2DM的糖代谢异常发生发展过程反映了胰岛β细胞早时相、基础和整体分泌功能逐渐衰退变化规律。 相似文献
46.
Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus. 相似文献
47.
Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus. 相似文献
48.
Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus. 相似文献
49.
高妍 《中华内分泌代谢杂志》2008,24(4)
作为经济迅速发展中的国家,中国糖尿病患病人数在迅速增加,并且发病年龄不断年轻化.其血管合并症是糖尿病致残致死的主要原因. 相似文献
50.
Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus. 相似文献